About Savara

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Our goal is to become a leader in rare respiratory disease therapeutics through the development and commercialization of novel, best-in-class medicines that address unmet medical needs in this field.


Management

Mr. Pauls has served as Savara’s Chief Executive Officer since December 2020, Chair of the Board of Directors since September 2020, and the company’s Interim Chief Executive Officer from September 2020 to December 2020. He has been a member of Savara’s Board of Directors since April 2017 and was Chair of the Mast Therapeutics (NYSE: MAST) Board of Directors (Savara closed a reverse merger with Mast Therapeutics in April 2017). Previously, Mr. Pauls was the Founder of Spartan Biopharma Insights, LLC, where he provided strategic advice to institutional investors and company management teams on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. He also previously served on the Zyla Life Sciences Board of Directors, which merged with Assertio Therapeutics in 2020. Prior to that, Mr. Pauls was President and Chief Executive Officer and, from October 2015 to November 2019, a member of the Strongbridge Biopharma plc Board of Directors. Strongbridge was a publicly traded rare-disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare respiratory diseases. Prior to Insmed, he worked at Shire Pharmaceuticals most recently as Senior Vice President, Head of Global Commercial Operations. Earlier in his career, Mr. Pauls held senior U.S. and global commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

Dr. Chowdhury has served as Savara’s Chief Medical Officer since November 2019. Previously he was at AstraZeneca, where he held the position of Senior Vice President, Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late-Stage Development in Biopharmaceuticals. For 16 years prior to that, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), where he provided scientific and regulatory oversight of therapies for common and rare diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, rheumatoid arthritis, systemic lupus erythromatosis, and various autoimmune and inflammatory diseases. Dr. Chowdhury is a medical doctor and holds a Ph.D. in immunology. He completed Internal Medicine Residency training from the Wayne State University School of Medicine, Detroit, Michigan, and Fellowship training in Allergy and Immunology from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland. He is double board-certified in Internal Medicine and Allergy and Immunology.

Mr. Lowrance has served as Savara’s Chief Financial Officer since November 2016. Previously, Mr. Lowrance was the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully integrated specialty pharmaceutical company. Prior to that, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company, where he was responsible for overseeing all aspects of the day-to-day operations, business development and growth endeavors, investor relations, and corporate communications. While there, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. Earlier in his career, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, where he oversaw all aspects of finance and accounting, business and growth strategy, and product development. Mr. Lowrance holds a CPA and has a B.B.A. in Accounting from the University of Georgia.

Dr. Clarke has served as Savara’s Executive Vice President, Global Technical Operations since September 2021. With more than four decades of experience in the Biopharma sector, he has extensive knowledge of late-stage development, manufacturing, supply chain and licensing in the U.S. and Europe. To date, Dr. Clarke has been part of licensing and launch teams for eight biological products in several different therapeutic areas. Prior to joining Savara, he held positions of increasing responsibility with companies in Europe and the US, including multi-national corporations and biopharmaceutical start-ups. He has held senior leadership roles at numerous companies, including Insmed, Savient Pharma, and Bayer Biologicals. Dr. Clarke holds a Ph.D. in Microbial Physiology from Imperial College, London.

Ms. Erickson has served as Savara’s Chief of Staff since October 2020 and is responsible for the company’s operational excellence, investor relations, corporate affairs, and advocacy efforts. Since joining the company in October 2018, she has held roles of increasing responsibility (including Vice President of Investor Relations and Corporate Communications and Head of Quality Assurance). Anne is a seasoned biopharmaceutical executive with deep expertise across a number of disciplines. Previously, she held leadership roles within corporate, consulting, and agency settings at companies such as Mirati Therapeutics, Halozyme, Pfizer, and Ogilvy.

Mr. LaPree has served as Savara’s Senior Vice President, Global Regulatory Affairs and Quality Assurance since August 2021. He has more than three decades of domestic and international drug development experience encompassing all aspects of global Regulatory Affairs and Quality Assurance. Prior to joining Savara, Mr. LaPree was SVP, Head of Global Regulatory Affairs and Quality Assurance at Annexon Biosciences. Prior to that he was VP, Head of Global Regulatory Affairs and Medical Writing at Astex Pharmaceuticals and previously served as SVP, Head of Global Regulatory Affairs at Jazz Pharmaceuticals. Mr. LaPree has held leadership roles of increasing responsibility at several other companies, including Shire Pharmaceuticals, Bristol-Myers Squibb Company, and Johnson & Johnson. He holds a B.S. in Chemistry from Rochester Institute of Technology and a M.S. in Environmental Sciences from the University of Rochester School of Medicine and Dentistry.

Ms. McCabe has served as Savara’s Head of Legal Affairs since March 2018. Prior to joining Savara, Ms. McCabe practiced corporate and securities law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, where she represented life sciences and technology companies in a variety of matters, including entity formation and structuring, venture capital financings, corporate governance, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. Ms. McCabe holds a B.S. in Accounting from Canisius College and a J.D. from the University of Texas School of Law.


Board of Directors

Mr. Pauls has served as Savara’s Chief Executive Officer since December 2020, Chair of the Board of Directors since September 2020, and the company’s Interim Chief Executive Officer from September 2020 to December 2020. He has been a member of Savara’s Board of Directors since April 2017 and was Chair of the Mast Therapeutics (NYSE: MAST) Board of Directors (Savara closed a reverse merger with Mast Therapeutics in April 2017). Previously, Mr. Pauls was the Founder of Spartan Biopharma Insights, LLC, where he provided strategic advice to institutional investors and company management teams on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. He also previously served on the Zyla Life Sciences Board of Directors, which merged with Assertio Therapeutics in 2020. Prior to that, Mr. Pauls was President and Chief Executive Officer and, from October 2015 to November 2019, a member of the Strongbridge Biopharma plc Board of Directors. Strongbridge was a publicly traded rare-disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded global biopharmaceutical company focused on rare respiratory diseases. Prior to Insmed, he worked at Shire Pharmaceuticals most recently as Senior Vice President, Head of Global Commercial Operations. Earlier in his career, Mr. Pauls held senior U.S. and global commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

Mr. Elam has served as a member of Savara’s Board of Directors since February 2009. He is currently a member of the Board of Directors and the President and Chief Executive Officer of Rezolute, Inc., a biopharmaceutical company focused on developing therapies for metabolic diseases with serious unmet needs. Prior to his tenure at Rezolute, Mr. Elam held senior executive roles within the pharmaceutical industry, including Senior Vice President and Head of the Pulmonary business unit of Nektar Therapeutics and President and Chief Executive Officer of a European medical device company. Earlier in his career, Mr. Elam was Co-Founder and Chief Financial Officer of E2open, Inc. and a partner in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Elam holds a J.D. from Harvard Law School and a B.A. from Howard University.

Mr. Hawkins has served as a member of Savara’s Board of Directors since October 2010. He is currently the President, Chief Executive Officer and Chair of the Board of Directors of Lumos Pharma, Inc., a clinical-stage biotechnology company focused on bringing novel therapies to patients with severe, rare, and genetic diseases whose medical needs are unmet. Mr. Hawkins also serves on the Board of Directors of Plus Therapeutics Inc. (formerly Cytori Therapeutics, Inc.), as well as several privately held life sciences companies. He previously served on the Board of Directors of SciClone Pharmaceuticals, Inc. Prior to his tenure with Lumos Pharma, Inc., Mr. Hawkins founded and advised numerous pharmaceutical companies, including Sensus, where he served as Co-Founder and Chair of the Board of Directors until it was sold to Pfizer. Previously, he was Founder, President, and Chief Executive Officer of Pharmaco, where he guided the company’s growth to more than 2,000 employees. The company later merged with PPD to form PPD Pharmaco, one of the largest clinical contract research organizations in the world. Mr. Hawkins holds a B.S. in Biology from Ohio University.

Dr. McCracken has served as Savara’s lead independent director since December 2019 and as a member of the company’s Board of Directors since October 2013. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. He also serves on the Board of Directors of Lumos Pharma, Inc. and Modalis Therapeutics Corporation, as well as the Board of Directors of the privately held companies Regimmune Inc. and Neuropore Therapies, Inc. Previously, Dr. McCracken was Vice President and Global Head of Business Development and Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for global in-licensing and out-licensing activities. Prior to that he served as General Manager, Roche Pharma Japan and Asia Regional Head, Roche Partnering. Prior to Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology, and a D.V.M. from The Ohio State University.

Mr. Ramsay has served as a member of Savara’s Board of Directors since April 2017 and served as a member of the Board of Directors of Mast Therapeutics, Inc. (Savara closed a reverse merger with Mast Therapeutics in April 2017). Mr. Ramsay currently provides consulting services to publicly traded and privately held biotechnology companies and serves on the Board of Directors of La Jolla Pharmaceutical Company and the privately held company Exuma Biotech, Inc. Previously, Mr. Ramsay served as Senior Vice Pesident and Chief Financial Officer of Bonti, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications. Prior to that, he was Chief Financial Officer of Halozyme Therapeutics, Inc., a biotechnology company developing and commercializing novel oncology therapies. Mr. Ramsay also served as Halozyme’s Vice President, Corporate Development. Before Halozyme, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life sciences industry, and as Vice President, Treasurer and Director, Corporate Finance with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), a multinational specialty pharmaceutical company. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. He holds a B.S. in Business Administration from the University of California, Berkeley, and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

Dr. Sun has served as a member of Savara’s Board of Directors since December 2019. Dr. Sun is a Managing Director at Bain Capital Life Sciences, LP and serves on the Board of Directors of Arcutis Biotherapeutics and Annexon Biosciences. Prior to joining Bain Capital, Dr. Sun was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, he was a Vice President at BlackRock as a member of the Fundamental Equity division of the Alpha Strategies Group and Senior Analyst for the fundamental large cap growth equity team where he covered the healthcare sector. Prior to BlackRock, Dr. Sun was a Senior Healthcare Analyst at Citadel and Alyeska Investment Group. He also worked as a pharmaceutical equity Research Analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. He began his career as a Senior Scientist at Ironwood Pharmaceuticals, where he was involved in the discovery and development of Linzess, a drug for irritable bowel syndrome. Dr. Sun holds a Ph.D. in chemistry and chemical biology from Harvard University and was an NIH post-doctoral fellow in biological chemistry and molecular pharmacology at Harvard Medical School. He also received an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry.

Dr. An van Es-Johansson has served on Savara’s Board of Directors since December 2019. Most recently, she was the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease. She currently serves on the Board of Directors at Plus Therapeutics, Inc., Lumos Pharma, Inc., IRLAB Therapeutics AB and the privately held company Agendia BV. Previously, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR medical affairs for specialty care and partner products. Prior to her time at Sobi, Dr. van Es-Johansson served in leadership positions at large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016 she was a member of the scientific advisory board for Uppsala BIO. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.


Learn about our clinical advisory board

Meet our clinical advisors